The flavonoid quercetin: Possible solution for anthracycline-induced cardiotoxicity and multidrug resistance

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 1149-1159

  Czepas, Jan ^a   Gwoździński, Krzysztof ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Anthracycline; Antioxidant; Cardiotoxicity; Flavonoid; Multidrug resistance; Quercetin

Indexed keywords

ANTHRACYCLINE; CARDIOTOXIN; FLAVONOID; QUERCETIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN; MULTIDRUG RESISTANCE; OXIDATIVE STRESS; PHYSIOLOGY;

ANIMALS; ANTHRACYCLINES; CARDIOTOXINS; DRUG RESISTANCE, MULTIPLE; FLAVONOIDS; HUMANS; OXIDATIVE STRESS; QUERCETIN;

EID: 84916239106     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.013     Document Type: Review

References (129)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
2. Costa V.M., Carvalho F., Duarte J.A., de Lourdes Bastos M., Remião F. The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem Res Toxicol 2013, 26:1285-1311. [dx.doi.org/10.1021/tx400130v].
3. Raschi E., Vasina V., Ursino M.G., Boriani G., Martoni A., De Ponti F. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010, 125:196-218.
4. Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 2001, 36:483-493.
5. Ryu J.S., Lee H.S., Hong Y.-S., Lee J.J., Sohn U.D., Kim T.Y. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X Hyrubicin). Cancer Chemother Pharmacol 2006, 57:811-818.
6. Rossato L.G., Costa V.M., de Pinho P.G., Arbo M.D., de Freitas V., Vilain L., et al. The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Arch Toxicol 2013, 87:1809-1820. 10.1007/s00204-013-1040-6.
7. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013, 65(2):157-170. 10.1111/j.2042-7158.2012.01567.x.
8. Cao J., Cui S., Li S., Du C., Tian J., Wan S., et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res 2013, 73(4):1362-1373. 10.1158/0008-5472.CAN-12-2072.
9. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337. 10.1186/1471-2407-10-337.
10. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010, 12(5):CD005006. 10.1002/14651858.CD 06.pub4 0050.
11. Berthiaume J.M., Oliveira P.J., Fariss M.W., Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 2005, 5(3):257-267.
12. Legha S.S., Wang Y.M., Mackay B., Ewer M., Hortobagyi G.N., Benjamin R.S., et al. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 1982, 393:411-418.
13. Myers C., Bonow R., Palmeri S., Jenkins J., Corden B., Locker G., et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983, 10:53-55.
14. Sung L., Tomlinson G.A., Greenberg M.L., Koren G., Judd P., Ota S., et al. Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer 2007, 43(8):1269-1275.
15. Machado V., Cabral A., Monteiro P., Gonçalves L., Providência L.A. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol 2008, 27:1277-1296.
16. Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of high dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114(23):2474-2481.
17. Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48(11):2258-2262.
18. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., et al. Anthracycline induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55(3):213-220. 10.1016/j.jacc.2009.03.095.
19. Ludke A.R., Al-Shudiefat A.A., Dhingra S., Jassal D.S., Singal P.K. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 2009, 87(10):756-763. 10.1139/Y09-059.
20. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, 15(6):CD003917. 10.1002/14651858.CD003917.pub4.
21. Kik K., Szmigiero L. Dexrazoxane (ICRF-187)-a cardioprotectant and modulator of action of some anticancer drugs. Postepy Hig Med Dosw (Online) 2006, 60:584-590.
22. ® (dexrazoxane) use in clinical practice. Support Care Cancer 2012, 20:1109-1112.
23. Roti Roti E.C., Salih S.M. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biol Reprod 2012, 86(3):96. 10.1095/biolreprod.111.097030.
24. Sargent J.M., Williamson C.J., Yardley C., Taylor C.G., Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukemia line, K562. Br J Cancer 2001, 84:959-964.
25. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
26. Stěrba M., Popelová O., Vávrová A., Jirkovský E., Kovaříková P., Geršl V., et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013, 18:899-929. 10.1089/ars.2012.4795.
27. Octavia Y., Tocchetti C., Gabrielson K., Janssens S., Crijns H., Moens A. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012, 52:1213-1225.
28. Suganuma M., Saha A., Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 2011, 102(2):317-323.
29. Slimestad R., Fossen T., Vågen I.M. Onions: a source of unique dietary flavonoids. J Agric Food Chem 2007, 55:10067-10080.
30. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin, Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004, 24:851-874.
31. Russo P., Del Bufalo A., Cesario A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Curr Med Chem 2012, 19(31):5287-5293.
32. Kelly G.S. Quercetin Monograph. Altern Med Rev 2011, 16:172-194.
33. Bors W., Heller W., Michel C., Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol 1990, 186:343-355.
34. Heijnen C.G., Haenen G.R., Vekemans J.A., Bast A. Peroxynitrite scavenging of flavonoids: structure activity relationship. Environ Toxicol Pharmacol 2001, 10(4):199-206.
35. Amić D., Davidović-Amić D., Bešlo D., Rastija V., Lučić B., Trinajstić N. SAR and QSAR of the antioxidant activity of flavonoids. Curr Med Chem 2007, 14:827-845.
36. Procházková D., Boušová I., Wilhelmová N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia 2011, 82:513-523.
37. Czaplińska M., Czepas J., Gwoździński K. Structure, antioxidative and anticancer properties of flavonoids. Postepy Biochem 2012, 58(3):235-244.
38. Wiczkowski W., Romaszko J., Bucinski A., Szawara-Nowak D., Honke J., Zielinski H., et al. Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 2008, 138:885-888.
39. Boyle S.P., Dobson V.L., Duthie S.J., Kyle J.A., Collins A.R. Absorption and DNA protective effects of flavonoid glycosides from an onion meal. Eur J Nutr 2000, 39(5):213-223.
40. Amić D., Lučić B. Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids. Bioorg Med Chem 2010, 18:28-35.
41. Hsieh C.-L., Peng C.-C., Chen K.-C., Peng R.Y. Rutin (quercetin rutinoside) induced protein-energy malnutrition in chronic kidney disease, but quercetin acted beneficially. J Agric Food Chem 2013, 61:7258-7267.
42. Ruiz M.J., Fernández M., Picó Y., Mañes J., Asensi M., Carda C., et al. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agric Food Chem 2009, 57:3180-3186.
43. Okamoto T. Safety of quercetin for clinical application (Review). Int J Mol Med 2005, 16:275-278.
44. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996, 2:659-668.
45. Jin F., Nieman D.C., Shanely R.A., Knab A.M., Austin M.D., Sha W. The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur J Clin Nutr 2010, 64:692-697. [http://dx.doi.org/10.1038/ejcn.2010.91].
46. Harwood M., Danielewska-Nikiel B., Borzelleca J.F., Flamm G.W., Williams G.M., Lines T.C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007, 45:2179-2205.
47. Mira L., Fernandez M.T., Santos M., Rocha R., Florêncio M.H., Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic Res 2002, 36:1199-1208. [http://dx.doi.org/10.1080/1071576021000016463].
48. Steffen Y., Gruber C., Schewe T., Sies H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 2008, 469:209-219. [http://dx.doi.org/10.1016/j.abb.2007.10.012].
49. Lotito S.B., Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?. Free Radic Biol Med 2006, 41:1727-1746.
50. Huang J., Wang S., Zhu M., Chen J., Zhu X. Effects of genistein, apigenin, quercetin, rutin and astilbin on serum uric acid levels and xanthine oxidase activities in normal and hyperuricemic mice. Food Chem Toxicol 2011, 49:1943-1947.
51. Lin C.-M., Chen C.-S., Chen C.-T., Liang Y.-C., Lin J.-K. Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem Biophys Res Commun 2002, 294:167-172.
52. Montoro P., Braca A., Pizza C., De Tommasi N. Structure-antioxidant activity relationships of flavonoids isolated from different plant species. Food Chem 2005, 92:349-355.
53. Pauff J.M., Hille R. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod 2009, 72:725-731.
54. Sadik C.D., Sies H., Schewe T. Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action. Biochem Pharmacol 2003, 65:773-781.
55. Ribeiro D., Freitas M., Tomé S.M., Silva A.M.S., Porto G., Cabrita E.J., et al. Inhibition of LOX by flavonoids: a structure-activity relationship study. Eur J Med Chem 2014, 72:137-145.
56. Redrejo-Rodriguez M., Tejeda-Cano A., Pinto M.D., Macias P. Lipoxygenase inhibition by flavonoids: semiempirical study of the structure-activity relation. J Mol Struc Theochem 2004, 674:121-124.
57. Filipe P., Patterson L.K., Bartels D.M., Hug G.L., Freitas J.P., Maziere J.-C., et al. Albumin-bound quercetin repairs vitamin E oxidized by apolipoprotein radicals in native HDL3 and LDL. Biochemistry 2007, 46:14305-14315.
58. Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 2006, 6:945-951. [http://dx.doi.org/10.2174/138955706777934937].
59. Crespo I., Garcia-Mediavilla M.V., Almar M., Gonzalez P., Tunon M.J., Sanchez-Campos S., et al. Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. Food Chem Toxicol 2008, 46:1555-1569.
60. Boesch-Saadatmandi C., Loboda A., Wagner A.E., Stachurska A., Jozkowicz A., Dulak J., et al. Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J Nutr Biochem 2011, 22:293-299. [http://dx.doi.org/10.1016/j.jnutbio.2010.02.008].
61. Heeba G.H., Mahmoud M.E., El Hanafy A.A. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-α. Toxicol Ind Health 2012, 30(6):551-560.
62. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52:673-751.
63. Ishizawa K., Yoshizumi M., Kawai Y., Terao J., Kihira Y., Ikeda Y., et al. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 2011, 115:466-470.
64. Trumbeckaite S., Bernatoniene J., Majiene D., Jakštas V., Savickas A., Toleikis A. The effect of flavonoids on rat heart mitochondrial function. Biomed Pharmacother 2006, 60:245-248.
65. Boots A.W., Kubben N., Haenen G.R., Bast A. Oxidized quercetin reacts with thiols rather than with ascorbate: implication for quercetin supplementation. Biochem Biophys Res Commun 2003, 308:560-565.
66. Jacobs H., Moalin M., Bast A., van der Vijgh W.J.F., Haenen G.R. An essential difference between the flavonoids mono-HER and quercetin in their interplay with the endogenous antioxidant network. PLoS One 2010, 5:e13880. [http://dx.doi.org/10.1371/journal.pone.0013880].
67. Boots A.W., Li H., Schins R.P.F., Duffin R., Heemskerk J.W.M., Bast A., et al. The quercetin paradox. Toxicol Appl Pharmacol 2007, 222:89-96.
68. Conklin K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004, 3(4):294-300.
69. Conklin K.A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000, 37(1):1-18.
70. Choi E.J., Bae S.M., Ahn W.S. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res 2008, 31:1281-1285. [http://dx.doi.org/10.1007/s12272-001-2107-0].
71. Lee-Hilz Y.Y., Boerboom A.M., Westphal A.H., Berkel W.J., Aarts J.M., Rietjens I.M. Pro-oxidant activity of flavonoids induces EpRE-mediated gene expression. Chem Res Toxicol 2006, 19:1499-1505. [http://dx.doi.org/10.1021/tx060157q].
72. Galati G., Sabzevari O., Wilson J.X., O'Brien P.J. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002, 177:91-104.
73. Mendoza E.E., Burd R. Quercetin as a systemic chemopreventative agent: structural and functional mechanisms. Mini Rev Med Chem 2011, 11(14):1216-1221.
74. Bansal T., Jaggi M., Khar R.K., Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharmaceut Sci 2009, 12:46-78.
75. van Zanden J.J., Wortelboer H.M., Bijlsma S., Punt A., Usta M., Bladeren P.J., et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005, 69:699-708.
76. Cooray H.C., Janvilisri T., van Veen H.W., Hladky S.B., Barrand M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 2004, 317:269-275.
77. Mojzisová G., Mirossay L., Kucerová D., Kyselovic J., Mirossay A., Mojzis J. Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity. Phytother Res 2006, 20:110-114.
78. Mojzisová G., Sarisský M., Mirossay L., Martinka P., Mojzis J. Effect of flavonoids on daunorubicin-induced toxicity in H9c2 cardiomyoblasts. Phytother Res 2009, 23:136-139.
79. Guzy J., Kusnír J., Mareková M., Chavková Z., Dubayová K., Mojzisová G., et al. Effect of quercetin on daunorubicin-induced heart mitochondria changes in rats. Physiol Res 2003, 52(6):773-780.
80. Chung S.Y., Sung M.K., Kim N.H., Jang J.O., Go E.J., Lee H.J. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005, 28:823-828.
81. Ishii K., Tanaka S., Kagami K., Henmi K., Toyoda H., Kaise T., et al. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest 2010, 28:220-229. 10.3109/07357900902744486.
82. Efferth T., Davey M., Olbrich A., Rücker G., Gebhart E., Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002, 28:160-168.
83. Borska S., Sopel M., Chmielewska M., Zabel M., Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010, 15:857-870. 10.3390/molecules15020857.
84. Kitagawa S., Nabekura T., Takahashi T., Nakamura Y., Sakamoto H., Tano H., et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 2005, 28(12):2274-2278.
85. Nguyen H., Zhang S., Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003, 92(2):250-257.
86. Cole S.P.C., Deeley R.G. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006, 27(8):438-446.
87. van Zanden J.J., Geraets L., Wortelboer H.M., van Bladeren P.J., Rietjens I.M.C.M., Cnubben N.H.P. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 2004, 67:1607-1617.
88. Wang S.-Q., Han X.-Z., Li X., Ren D.-M., Wang X.-N., Lou H-X. Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells. Bioorg Med Chem Lett 2010, 20:6411-6415.
89. Wang S.-Q., Zhu X.-F., Wang X.-N., Shen T., Xiang F., Lou H.-X. Flavonoids from Malus hupehensis and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells. Phytochemistry 2013, 87:119-125.
90. Chen J.-Y., Hu R.-Y., Chou H.-C. Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci 2013, 20:95. 10.1186/1423-0127-20-95.
91. Salvatorelli E., Menna P., Cascegna S., Liberi G., Calafiore A.M., Gianni L., et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 2006, 318:424-433. [http://dx.doi.org/10.1124/jpet.106.103846].
92. Kaiserová H., Šimůnek T., van der Vijgh W.J.F., Bast A., Kvasničková E. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 2007, 1772:1065-1074.
93. Psotová J., Chlopčíková Š., Miketová P., Hrbáč J., Šimánek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes: part III. Apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother Res 2004, 18:516-521.
94. Long L.H., Clement M.V., Halliwell B. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate, (+)-catechin, and quercetin to commonly used cell culture media. Biochem Biophys Res Commun 2000, 273:50-53.
95. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch Biochem Biophys 2008, 476:107-112.
96. Vaclavikova R., Kondrova E., Ehrlichova M., Boumendjel A., Kovar J., Stopka P., et al. The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 2008, 16:2034-2042.
97. Matouk A.I., Taye A., Heeba G.H., El-Moselhy M.A. Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ Toxicol Pharmacol 2013, 36:443-450.
98. Chen Z., Qian S., Chen X., Chen J., Zhang G., Zhong H. Investigation on the interaction between anthracyclines and DNA in the presence of quercetin by resonance light scattering technique and its analytical application. Curr Anal Chem 2013, 9(1):135-142.
99. Staedler D., Idrizi E., Kenzaoui B.H., Juillerat-Jeanneret L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 2011, 68:1161-1172.
100. Mihaila M., Bostan M., Hotnog D., Ferdes M., Brasoveanu L.I. Real-time analysis of quercetin, resveratrol and/or doxorubicin effects in mcf-7 cells. Rom Biotechnol Lett 2013, 18:8106-8114.
101. Li S.-Z., Li K., Zhang J.-H., Dong Z. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. Anti-Cancer Agents Med Chem 2013, 13:352-355. 10.2174/1871520611313020020.
102. Du G., Lin H., Wang M., Zhang S., Wu X., Lu L., et al. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol 2010, 65:277-287.
103. Du G., Lin H., Yang Y., Zhang S., Wu X., Wang M., et al. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 2010, 10:819-826.
104. Choi J.-S., Piao Y.-J., Kang K.W. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011, 34:607-613.
105. van Zanden J.J., van der Woude H., Vaessen J., Usta M., Wortelboer H.M., Cnubben N.H.P., et al. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 2007, 74:345-351.
106. Park H.S., Oh J.H., Lee Jh, Lee Y.J. Minor effects of the citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats. Pharmazie 2011, 66:424-429. [http://dx.doi.org/10.1691/ph.2011.0857].
107. Ewer M.S., Benjamin R.S. Doxorubicin cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention. Cancer and the Heart 2006, 9-32. BC Decker, Hamilton, ON, Canada. M.S. Ewer, E. Yeh (Eds.).
108. Salvatorelli E., Guarnieri S., Menna P., Liberi G., Calafiore A.M., Mariggiò M.A., et al. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart, Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 2006, 281:10990-11001.
109. Menna P., Salvatorelli E., Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 2008, 21:978-989. 10.1021/tx800002r.
110. Salvatorelli E., Menna P., Lusini M., Covino E., Minotti G. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 2009, 329:175-184. 10.1124/jpet.108.149260.
111. Borchmann P., Hübel K., Schnell R., Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997, 35:80-83.
112. Çelik H., Arinç E. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect. J Pharm Pharm Sci 2008, 11:68-82.
113. Çelik H., Arinç E. Evaluation of the protective effects of quercetin, rutin, naringenin, resveratrol and trolox against idarubicin-induced DNA damage. J Pharm Pharm Sci 2010, 13:231-241.
114. Tabaczar S., Pieniaz˙ek A., Czepas J., Piasecka-Zelga J., Gwoździński K., Koceva-Chyła A. Quercetin attenuates oxidative stress in the blood plasma of rats bearing DMBA-induced mammary cancer and treated with a combination of doxorubicin and docetaxel. Gen Physiol Biophys 2013, 32(4):535-543. [doi:10.4149/gpb_2013048].
115. Kebieche M., Lakroun Z., Lahouel M., Bouayed J., Meraihi Z., Soulimani R. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. Exp Toxicol Pathol 2009, 61(2):161-167. 10.1016/j.etp.2008.06.002.
116. Wang G., Zhang J., Liu L., Sharma S., Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One 2012, 7:e51764.
117. Murakami A., Ashida H., Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008, 269:315-325. [http://dx.doi.org/10.1016/j.canlet.2008.03.046].
118. Ebert B., Seidel A., Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 2007, 96(2):227-236. 10.1093/toxsci/kfl147.
119. Chou C.-C., Yang J.-S., Lu H.-F., Ip S.-W., Lo C., Wu C.-C., et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch Pharm Res 2010, 33(8):1181-1191.
120. Kamaraj S., Vinodhkumar R., Anandakumar P., Jagan S., Ramakrishnan G., Devaki T. The effects of quercetin on antioxidant status and tumor markers in the lung and serum of mice treated with benzo(a)pyrene. Biol Pharm Bull 2007, 30(12):2268-2273.
121. Devipriya S., Ganapathy V., Shyamaladevi C.S. Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin. Chem Biol Interact 2006, 162:106-113.
122. Boly R., Gras T., Lamkami T., Guissou P., Serteyn D., Kiss R., et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol 2011, 38:833-842.
123. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81:230S-242S.
124. Sesink A.L., Arts I.C., de Boer V.C., Breedveld P., Schellens J.H., Hollman P.C., et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005, 67:1999-2006.
125. An G., Gallegos J., Morris M.E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos 2011, 39(3):426-432.
126. Jain S., Jain A.K., Pohekar M., Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: Implications for drug-induced cardiotoxicity and nephrotoxicity. Free Rad Biol Med 2013, 65:117-130.
127. Yang W., Ahmed M., Tasawwar B., Levchenko T., Sawant R.R., Torchilin V., et al. Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: Reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J Control Release 2012, 160:239-244.
128. Yang W., Ahmed M., Tasawwar B., Levchenko T., Sawant R.R., Collins M., et al. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int J Hyperthermia 2011, 27(6):527-538. 10.3109/02656736.2011.582474.
129. Chen C., Zhou J., Ji C. Quercetin: a potential drug to reverse multidrug resistance. Life Sci 2010, 87:333-338.